Virrx, Inc.

Chesterfield, MO 63017

SBIR Award Summary

Total Number of Awards 10
Total Value of Awards $2.1MM
First Award Date 09/01/99
Most Recent Award Date 08/01/09

Key Personnel

Last Name Name Awards Contact
Wold William Sm Wold 5
Ying Baoling Ying 1
Doronin Konstantin Doronin 1
Green Michael Green 1
Lichtenstein Drew L. Lichtenstein 1
Cao Feng Cao 1

10 Awards Won

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-08-051
Budget: 08/01/09 - 07/31/10
PI: Feng Cao

DESCRIPTION (provided by applicant): Hepatitis B virus (HBV) is a hepatotropic DNA virus that replicates by reverse transcription. It chronically infects over 350 million people worldwide and causes 600,000 deaths annually. Current therapies for HBV infection use interferon 1 or one of five nucleoside analogs. Neither form of treatment cures HBV...

Phase 1 STTR

Agency: Department of Health & Human Services
Topic: PA-06-21
Budget: 08/15/07 - 07/31/08

DESCRIPTION (provided by applicant): Human adenoviruses (Ads) are a significant problem in immunosuppressed humans, especially in children undergoing allogeneic stem cell transplants. About 20% of these pediatric patients develop disseminated Ad infections and about half of the patients die. There are no anti-viral drugs approved to treat these ...

Phase 1 STTR

Agency: Department of Health & Human Services
Topic:
Budget: 08/17/04 - 07/31/06

DESCRIPTION (provided by applicant): Adenovirus vectors have also been evaluated for their efficacy in treating cancer. As cancer is the second leading cause of death in the U.S. and current therapeutics are not always sufficient, new cancer therapies are desired. Replication-competent oncolytic adenovirus vectors have been designed to kill canc...

Phase 1 STTR

Agency: Department of Health & Human Services
Topic:
Budget: 04/01/04 - 03/31/06

DESCRIPTION (provided by applicant): We have constructed an oncolytic adenovirus vector named "KD3" that replicates selectively in cancer cells as opposed to normal cells because of a mutation in the adenovirus E1A gene that prevents E1A proteins from deregulating the cell cycle in normal cells. KD3 was designed to overexpress the E3-11.6K prot...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 03/12/04 - 02/28/06

DESCRIPTION (provided by applicant): We have developed replication-competent oncolytic adenovirus (Ad) vectors for cancer gene therapy that are designed to spread rapidly from cell to cell by virtue of the fact that they express ADP, an Ad protein that is expressed predominantly late in infection and that is required for efficient virus relea...

Phase 2 STTR

Agency: Department of Health & Human Services
Topic:
Budget: 07/03/03 - 06/30/05

DESCRIPTION (provided by applicant): We have developed several tumor-specific and tissue-specific replication-competent adenoviruses (Ad) vectors for cancer gene therapy. One vector, named KD3, has a mutation in the E1A gene such that KD3 cannot replicate in, and destroy, "normal" cells. However, KD3 can replicate in cancer cells because they h...

Phase 1 STTR

Agency: Department of Health & Human Services
Topic:
Budget: 05/09/03 - 04/30/05

DESCRIPTION (provided by applicant): The efficacy of molecular chaperones as adjuvants for the induction of anti-tumor immunity has been demonstrated in many laboratories over the last two decades. Similarly, the exploration of the therapeutic use of poxviruses in cancer treatment has a long and diverse history. These findings have led us to hy...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: RFA-AI-02-05
Budget: 09/15/02 - 09/14/04

DESCRIPTION (provided by applicant): The events on and following September 11, 2001 have revealed our nation's vulnerability to terrorist attacks. Although much talked about during the past decade, the threat of a bioterrorist attack against the United States was not realized until the intentional distribution of weapons grade Bacillus anthraci...

Phase 2 STTR

Agency: Department of Health & Human Services
Topic:
Budget: 07/08/02 - 06/30/03

DESCRIPTION (provided by applicant): We have developed several tumor-specific and tissue-specific replication-competent adenoviruses (Ad) vectors for cancer gene therapy. One vector, named KD3, has a mutation in the E1A gene such that KD3 cannot replicate in, and destroy, "normal" cells. However, KD3 can replicate in cancer cells because they h...

Phase 1 STTR

Agency: Department of Health & Human Services
Topic:
Budget: 09/01/99 - 08/31/01

We have constructed two novel human adenovirus replication competent vectors, named KD1 and KD3, for use in treating different human cancers. These vectors kill cancer cells, spread rapidly from cell-to-cell, and have minimal effect on non-cancerous cells, Unlike most adenovirus vectors which express a foreign gene and cannot replicate, KD1 and ...

Load More